دورية أكاديمية
أعرض في EDS

Enfortumab vedotin-induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature.

التفاصيل البيبلوغرافية
العنوان: Enfortumab vedotin-induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature.
المؤلفون: Sport C; Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA., Clawson RC; Department of Dermatology, Virginia Commonwealth University Health System, Richmond, Virginia, USA., Tisdale LE; Department of Dermatology, Virginia Commonwealth University Health System, Richmond, Virginia, USA., Melson JW; Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA.; Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, Virginia, USA., Mochel MC; Department of Dermatology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.; Department of Pathology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
المصدر: Journal of cutaneous pathology [J Cutan Pathol] 2024 Jul 15. Date of Electronic Publication: 2024 Jul 15.
Publication Model: Ahead of Print
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0425124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0560 (Electronic) Linking ISSN: 03036987 NLM ISO Abbreviation: J Cutan Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: Malden, MA : Wiley
Original Publication: Copenhagen, Blackwell Munksgaard.
مستخلص: Enfortumab vedotin (EV), a nectin-4-binding agent that affects microtubules, has become standard therapy for advanced urothelial carcinoma. The agent, now given in combination with pembrolizumab, frequently induces cutaneous reactions. Here, we report a severe EV-induced cutaneous eruption. A 58-year-old woman with metastatic urothelial carcinoma developed a rash after receiving simultaneous first doses of EV and pembrolizumab. The eruption began on the flank and spread to involve her trunk and extremities with prominent involvement of folds, including the axillae and medial thighs. Skin biopsy revealed extensive vacuolar alteration of the basal epidermis and numerous epidermal keratinocytic mitotic figures, often suprabasilar, including ring and "starburst" forms. The findings supported a diagnosis of EV-induced eruption. With EV cessation and systemic corticosteroids, the rash resolved over a few weeks. Pembrolizumab was restarted as monotherapy, and the patient's cancer showed a significant radiographic treatment response at 3 months. An emerging literature of small series and case reports, largely from oncologic literature, presents the histopathology of EV-induced cutaneous eruption as a vacuolar interface dermatitis with the inconsistently reported feature of arrested mitotic figures. This case study demonstrates distinctive clinical and histopathologic features of EV-induced eruption, which may inform dermatologic and oncologic management.
(© 2024 The Author(s). Journal of Cutaneous Pathology published by John Wiley & Sons Ltd.)
References: Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125‐1135. doi:10.1056/NEJMOA2035807.
Rosenberg JE, Powles T, Sonpavde GP, et al. EV‐301 long‐term outcomes: 24‐month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047‐1054. doi:10.1016/j.annonc.2023.08.016.
Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875‐888. doi:10.1056/NEJMoa2312117.
Challita‐Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody‐drug conjugate targeting nectin‐4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003‐3013. doi:10.1158/0008‐5472.CAN‐15‐1313.
Heath EI, Rosenberg JE. The biology and rationale of targeting nectin‐4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93‐103. doi:10.1038/s41585‐020‐00394‐5.
Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of dermatologic events associated with the nectin‐4‐directed antibody‐drug conjugate enfortumab vedotin. Oncologist. 2022;27(3):e223‐e232. doi:10.1093/oncolo/oyac001.
Ingen‐Housz‐Oro S, Thibault C, Sohier P, Dupin N. Regarding “Management of dermatologic events associated with the nectin‐4‐directed antibody‐drug conjugate enfortumab vedotin”. Oncologist. 2022;27(10):e825‐e826. doi:10.1093/oncolo/oyac170.
Guerrois F, Thibault C, Lheure C, et al. Life‐threatening skin reaction with enfortumab vedotin: six cases. Eur J Cancer. 2022;167:168‐171. doi:10.1016/j.ejca.2022.02.019.
Hirotsu KE, Rana J, Wang JY, et al. Clinicopathologic characterization of enfortumab vedotin‐associated cutaneous toxicity in patients with urothelial carcinoma. J Am Acad Dermatol. 2021;85(6):1610‐1611. doi:10.1016/j.jaad.2020.11.067.
Wu S, Adamson AS. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. Dermatol Online J. 2019;25(2):6.
Penny CL, Quow K, Rundle CW, et al. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. Br J Dermatol. 2022;187(1):126‐127. doi:10.1111/bjd.21022.
Hasui KI, Kawakami Y, Miyake T, et al. Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin. J Dermatol. 2023;50(4):e115‐e116. doi:10.1111/1346‐8138.16646.
Viscuse PV, Marques‐Piubelli ML, Heberton MM, et al. Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens‐Johnson syndrome/toxic epidermal necrolysis to dermal hypersensitivity reaction. Front Oncol. 2021;11:621591. doi:10.3389/fonc.2021.621591.
FDA. FDA approves enfortumab vedotin‐ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. Accessed April 1, 2024. https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐approves‐enfortumab‐vedotin‐ejfv‐pembrolizumab‐locally‐advanced‐or‐metastatic‐urothelial‐cancer.
Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22‐31. doi:10.1200/JCO.22.01643.
Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158‐176. doi:10.1111/cup.12858.
Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 2016;43(9):787‐791. doi:10.1111/cup.12735.
Vlachou E, Matoso A, McConkey D, et al. Enfortumab vedotin‐related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single‐center experience and review of the literature. Eur Urol Open Sci. 2023;49:100‐103. doi:10.1016/j.euros.2023.01.002.
Daniels JA, Gibson MK, Xu L, et al. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol. 2008;32(3):473‐477. doi:10.1097/PAS.0b013e3181582331.
Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524‐529. doi:10.1016/j.jaad.2008.05.018.
Bhawan J, Petry J, Rybak ME. Histologic changes induced in skin by extravasation of doxorubicin (adriamycin). J Cutan Pathol. 1989;16(3):158‐163. doi:10.1111/j.1600‐0560.1989.tb00032.x.
Fitzpatrick JE. New histopathologic findings in drug eruptions. Dermatol Clin. 1992;10(1):19‐36. doi:10.1016/S0733‐8635(18)30352‐8.
Yokel BK, Friedman KJ, Farmer ER, Hood AF. Cutaneous pathology following etoposide therapy. J Cutan Pathol. 1987;14(6):326‐330. doi:10.1111/j.1600‐0560.1987.tb01532.x.
Plummer RS, Shea CR. Dermatopathologic effects of taxane therapy. J Am Acad Dermatol. 2011;65(3):592‐596. doi:10.1016/j.jaad.2010.07.033.
Prieto‐Torres L, Llamas‐Velasco M, Machan S, et al. Taxanes‐induced cutaneous eruption: another histopathologic mimicker of malignancy. J Eur Acad Dermatol Venereol. 2016;30(4):638‐644. doi:10.1111/jdv.13475.
Millsop JW, Sharon VR, Petukhova T, Fung MA, Kiuru M. Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma. J Cutan Pathol. 2016;43(12):1215‐1219. doi:10.1111/cup.12833.
فهرسة مساهمة: Keywords: chemotherapy; drug eruption; ring mitosis
تواريخ الأحداث: Date Created: 20240716 Latest Revision: 20240716
رمز التحديث: 20240716
DOI: 10.1111/cup.14689
PMID: 39010671
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-0560
DOI:10.1111/cup.14689